March 16, 2011 – Revalesio Corporation announced that research related to the use of RNS60, its novel anti-inflammatory, will be featured in two poster presentations at the Annual Meeting of the American Academy of Allergy Asthma and Immunology (AAAAI) in San Francisco on March 18-22.AAAAI is the largest professional organization in the United States devoted to the specialty of allergy and immunology. It has nearly 6,500 members in the United States, Canada and 60 other countries.
Revalesio will present findings that demonstrate the novel anti-inflammatory activity of charge-stabilized nanostructures both in a preclinical model of allergic asthma and in cell culture experiments. These data suggest that Revalesio’s novel therapeutic RNS60 provides an opportunity for the development of a new generation of low-risk therapeutics for inflammatory pulmonary diseases.
In the preclinical model of asthma, RNS60 showed significant efficacy in the reduction of key inflammatory cytokines, including interleukin-6, interleukin-4, tumor necrosis factor-α (TNF-α), eotaxin and other cytokines known to be drivers of asthma. In addition to reducing inflammatory cytokines, RNS60 improved respiratory parameters compared to treatment with the inhaled corticosteroid budesonide... Revalesio's Press Release -
